PGG-glucan, a leukocyte-specific immunostimulant, does not potentiate GVHD or allograft rejection

Journal of Surgical Research

Volumn 62, Issue 2, 1996, Pages 179-183

  Washburn, W Kenneth ^a   Otsu, Ichiro ^a   Gottschalk, Rita ^a   Monaco, Anthony P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLUCAN; LYMPHOCYTE ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GRAFT INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INTESTINE TRANSPLANTATION; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RAT; SKIN TRANSPLANTATION;

EID: 0030002064     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0192     Document Type: Article

References (25)

1. Shulkin, D. J., Kinosian, B., Glick, H., Glen-Puschett, C., Daly, J., and Eisenberg, J. M. The economic impact of infections: an analysis of hospital costs and charges in surgical patients with cancer. Arch. Surg. 128: 449, 1993.
2. Nicholson, V., and Johnson, P. C. Infectious complications in solid organ transplant recipients. Surg. Clin. N. Am. 74: 1223, 1994.
3. Babineau, T. J., Marcello, P., Swails, W., Kenler, A., Bistrian, B., and Forse, R. A. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high risk surgical patients. Ann. Surg. 220: 601, 1994.
4. Babineau, T. J., Hackford, A., Kenler, A., et al. A phase II multicenter, double-blinded, placebo-controlled study of the three dosages of an immunomodulator (PGG-glucan) in high risk surgical patients. Arch. Surg. 129: 1204, 1994.
5. Riggi, S. J., and DiLuzio, N. R. Identification of a reticuloendothelial stimulating agent in zymosan. Am. J. Physiol. 200: 297, 1961.
6. Bacon, J. S. D., Farmer, V. C., Jones, D., and Taylor, I. F. The glucan component of the cell wall of Baker's yeast (Saccharomyces cerevisiae) considered in relation to its ultrastructure. Biochem. J. 114: 556, 1969.
7. Jamas, S., Chen Y-C.J., von der Osten, C. H., Sinskey, A. J., and Rha, C. K. Spectral analysis of glucan produced by wild-type and mutant Saccharomyces cerevisiae. Carbohydr. Polysci. 13: 207, 1969.
8. Shah, P. M. Effects of betafectin on the phagocytosis of stapholococcus aureus by human granulocytes and human peritoneal macrophages. Worcester, MA: Alpha-Beta Technology, Inc., 1989 (Aug). Report No. CP-3/S-11/01/89.
9. Dinarello, C. A. Stimulation of IL-1 and TNF-alpha synthesis by Betafectin. Worcester, MA: Alpha-Beta Technology, Inc., 1991 (Aug). Report No. CP-2/D-09/25/89.
10. Onderdonk, A. B., Cisneros, R. L., Hinkson, P., and Ostroff, G. Anti-effective effect of Poly-1-6-Glucotriosyl-1-3-Glycopyranose Glucan in vivo. Infect. Immunol. 60: 1642, 1992.
11. IND 4190 Betafectin, Information Amendment, Serial No. 005. Worcester, MA: Alpha-Beta Technology, Inc., 1992 (May) 18:3037-3039.
12. Nicolosi, R., Yoganathan, S., Wakshull, E., et al. A study to evaluate the safety, efficacy and pharmacokinetics of three dosages of Betafectin: Varying frequency, route of administration, duration of treatment, and formulation in healthy Cebus monkeys. Worcester, MA: Alpha-Beta Technology, Inc., 1992 (Oct). Report No. APK-1/NYWSR-10/29/92; IND 4190 BETAFECTIN, Information Amendment, Serial No. 011; 1992 (Nov) 4;1:412-427.
13. Nicolosi, R., Yoganathan, S., Wakshull, E., et al. A study to evaluate the safety, efficacy and pharmacokinetics of three dosages of Betafectin: Varying frequency, route of administration, duration of treatment, and formulation in healthy Cebus monkeys. Worcester, MA: Alpha-Beta Technology, Inc., 1992 (Oct). Report No. APK-1/NYWSR-10/29/92; IND 4190 BETAFECTIN, Information Amendment, Serial No. 011; 1992 (Nov) 4;1:412-427.
14. Pomposelli, F., Maki, T., Kiyoizumi, T., et al. Induction of graft-versus-host disease by small intestinal allotransplantation in rats. Transplantation 40: 343, 1985.
15. Ono, K., and Lindsey, E. S. Improved technique of heart transplantation in rats. J. Thor. Cardiovasc. Surg. 57: 225, 1969.
16. Monaco, A. P., Wood, M. L., Gray, J. G., and Russell, P. S. Studies on heterologous antilymphocyte serum in mice: II. Effect on the immune response. J. Immunol. 96: 229, 1966.
17. Gray, J. G., Monaco, A. P., Wood, M. L., and Russell, P. S. Studies on heterologous antilymphocyte serum in mice: I. In vitro and in vivo properties. J. Immunol. 96: 217, 1966.
18. Shaffer, D., Maki, T., DeMichele, S. J., et al. Studies in small bowel transplantation. Transplantation 45: 262, 1988.
19. Blakely, M. L., Shaffer, D., Ohzato, H., et al. Indefinite survival following small intestinal transplantation after intrathymic injection of the donor with recipient-type splenocytes in a rat model. Transplantation 59: 309, 1995.
20. Tolkoff-Rubin, N. E., and Rubin, H. R. Infections in the organ transplant recipient. In J. G. Cerilli (Ed), Organ Transplantation and Replacement. Philadelphia, Lippincott, 1988. Pp. 445-461.
21. Williams, D. L., and DiLuzio, N. R. Glucan-induced modification of experimental Staphlococcus aureus infection in normal, leukemic and immunosuppressed mice. Adv. Exp. Med. Biol. 121: 291, 1979.
22. Browder, W., Williams, D., Pretus, H., et al. Beneficial effect of enhanced macrophage function in the trauma patient. Ann. Surg. 211: 605, 1990.
23. Felippe, J., Silva, M., and Marciel, F., et al. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose(glucan) Surg. Gynecol. Obstet. 177: 383, 1993.
24. 4 production. J. Immunol. 141: 3170, 1988.
25. Mackin, W., Brunke-Reese, D., Gu, Y., Grotty, C., and Fisette, L. Enhanced microbicidal activity of human peripheral blood monocytes and neutrophils (PMN) after pre-treatment with PGG-glucan. Presented at the FASEB Experimental Biology 94. April 24-28, 1994, Anaheim, CA.